Sugi Predict

Sugi Predict / Compounds / SCHEMBL289312

SCHEMBL289312

SCHEMBL289312

O=C(O)C1CCC(=O)N1Cc1ccccc1Cl

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 3/20 0.65
▸ MAPT P10636 2/20 0.65
▸ GAA P10253 2/20 0.65
▸ MEN1 O00255 1/20 0.65
▸ KMT2A Q03164 1/20 0.65
▸ P2RX7 Q99572 4/20 0.63
▸ ALDH1A1 P00352 3/20 0.63
▸ LMNA P02545 1/20 0.63
▸ CYP2D6 P10635 5/20 0.61
▸ CYP2C19 P33261 5/20 0.61
▸ CYP2C9 P11712 4/20 0.61
▸ CYP3A4 P08684 3/20 0.59
▸ CYP1A2 P05177 3/20 0.59
▸ TSHR P16473 2/20 0.59
▸ TDP1 Q9NUW8 1/20 0.59
▸ GFER P55789 1/20 0.59
▸ USP2 O75604 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1613178 1.00 HTT (0.65) HTTMAPTGAAMEN1KMT2A
SCHEMBL19974857 0.90 HTT (0.64) HTTMAPTGAAMEN1KMT2A
SCHEMBL30061769 0.90 HTT (0.64) HTTMAPTGAAMEN1KMT2A
SCHEMBL1614091 0.84 P2RX7 (0.56) HTTMAPTGAAMEN1KMT2A
SCHEMBL288496 0.84 P2RX7 (0.56) HTTMAPTGAAMEN1KMT2A
SCHEMBL7217950 0.84 HTT (0.48) HTTMAPTGAAMEN1KMT2A
SCHEMBL17940635 0.84 P2RX7 (0.56) HTTMAPTGAAMEN1KMT2A
SCHEMBL289574 0.84 P2RX7 (0.56) GAAKMT2AP2RX7ALDH1A1CYP2D6
SCHEMBL288651 0.84 P2RX7 (0.56) GAAKMT2AP2RX7ALDH1A1CYP2D6
SCHEMBL288652 0.84 P2RX7 (0.56) GAAKMT2AP2RX7ALDH1A1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 — — US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 — — US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 — — US disclosed
CN-110062753-A Antiviral compounds 哈普洛根有限责任公司 2019-07-26 — — CN disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 — — US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 — — US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 — — EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 — — WO disclosed
EP-2427429-B1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS ABBVIE DEUTSCHLAND (DE) 2017-02-15 — — EP disclosed
US-9527811-B2 Carboxamide compounds and their use as calpain inhibitors AbbVie Deutschland GmbH & Co. KG (DE) 2016-12-27 — — US disclosed
EP-2516393-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS Abbott GmbH & Co. KG (DE) 2012-10-31 — — EP disclosed
US-8283363-B2 Carboxamide compounds and their use as calpain inhibitors ABBOTT LABORATORIES (US) 2012-10-09 — — US disclosed
US-8236798-B2 Carboxamide compounds and their use as calpain inhibitors ABBOTT GMBH & CO. KG (DE) 2012-08-07 — — US disclosed
CN-102482212-A Carboxamide compounds and their use as calpain inhibitors ABBOTT GMBH & CO KG 2012-05-30 — — CN disclosed
EP-2427429-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS Abbott GmbH & Co. KG (DE) 2012-03-14 — — EP disclosed
WO-2011076811-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS ABBOTT GMBH & CO. KG (DE) 2011-06-30 — — WO disclosed
US-20110152265-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V ABBOTT GMBH & CO. KG (DE) 2011-06-23 — — US disclosed
US-20110086879-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS ABBOTT GMBH & CO. KG (DE) 2011-04-14 — — US disclosed
WO-2010128102-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS ABBOTT GMBH & CO. KG (DE) 2010-11-11 — — WO disclosed
US-20100286146-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS ABBOTT GMBH & CO. KG (DE) 2010-11-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C HTT 3380/4885MAPT 4561/4885GAA 75/4885
US-20100286146-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS CAPN1, CAPN2, CAPNS1 HTT 408/4885MAPT 180/4885GAA 565/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C HTT 3569/4885MAPT 4673/4885GAA 107/4885
US-20110152265-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V CAPN2, CAPN1, CAPNS1 HTT 335/4885MAPT 967/4885GAA 1944/4885
US-20110086879-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS CAPN1, CAPN2, CAPNS1 HTT 408/4885MAPT 180/4885GAA 565/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C HTT 3380/4885MAPT 4561/4885GAA 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.